High Expression of SPAG6 Acts as a Pro-Tumor Factor and Associated With Poor Prognosis in Acute Myeloid Leukemia

IF 2.3 4区医学 Q3 HEMATOLOGY International Journal of Laboratory Hematology Pub Date : 2025-03-28 DOI:10.1111/ijlh.14457

Jie Luo, Haiqiu Zhao, Xiaoyan Zang, Lin Liu

{"title":"High Expression of SPAG6 Acts as a Pro-Tumor Factor and Associated With Poor Prognosis in Acute Myeloid Leukemia","authors":"Jie Luo, Haiqiu Zhao, Xiaoyan Zang, Lin Liu","doi":"10.1111/ijlh.14457","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Acute myeloid leukemia (AML) is a malignant hematological disease that has shown an increased prevalence in recent years. Despite advancements in treatment, significant limitations remain. Therefore, more information about AML mechanisms is essential to improve therapeutic strategies.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>RT-qPCR, IHC, and western blot were used to analyze SPAG6 expression levels. The association between SPAG6 expression and patient survival was evaluated using LeukemiaDB, GEPIA, and Bloodspot databases. Cell viability was detected by CCK-8 assay. Flow cytometry was applied to measure cell apoptosis and cell cycle.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Database analysis revealed elevated SPAG6 expression in AML. Subsequent RT-qPCR confirmed high SPAG6 expression in AML, MDS, MPN, and ALL samples. Clinical data analysis demonstrated a positive correlation between SPAG6 expression and risk stratification in AML patients. Notably, it was found that the overall survival time of AML patients with high SPAG6 expression was shorter than that of patients with low SPAG6 expression. Moreover, SPAG6 knockdown in the AML cell line HL60 promoted apoptosis and arrested the cell cycle in the G1 phase.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Therefore, we believe that SPAG6 may be a pro-tumor factor in AML.</p>\n </section>\n </div>","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":"47 4","pages":"680-689"},"PeriodicalIF":2.3000,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Laboratory Hematology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ijlh.14457","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Acute myeloid leukemia (AML) is a malignant hematological disease that has shown an increased prevalence in recent years. Despite advancements in treatment, significant limitations remain. Therefore, more information about AML mechanisms is essential to improve therapeutic strategies.

Methods

RT-qPCR, IHC, and western blot were used to analyze SPAG6 expression levels. The association between SPAG6 expression and patient survival was evaluated using LeukemiaDB, GEPIA, and Bloodspot databases. Cell viability was detected by CCK-8 assay. Flow cytometry was applied to measure cell apoptosis and cell cycle.

Results

Database analysis revealed elevated SPAG6 expression in AML. Subsequent RT-qPCR confirmed high SPAG6 expression in AML, MDS, MPN, and ALL samples. Clinical data analysis demonstrated a positive correlation between SPAG6 expression and risk stratification in AML patients. Notably, it was found that the overall survival time of AML patients with high SPAG6 expression was shorter than that of patients with low SPAG6 expression. Moreover, SPAG6 knockdown in the AML cell line HL60 promoted apoptosis and arrested the cell cycle in the G1 phase.

Conclusion

Therefore, we believe that SPAG6 may be a pro-tumor factor in AML.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

高表达的SPAG6在急性髓系白血病中作为促肿瘤因子并与不良预后相关。

背景：急性髓性白血病（AML）是一种恶性血液系统疾病，近年来发病率呈上升趋势。尽管在治疗方面取得了进展，但仍存在显著的局限性。因此，更多关于AML机制的信息对于改善治疗策略至关重要。方法：采用RT-qPCR、免疫组化（IHC）和western blot检测SPAG6的表达水平。使用LeukemiaDB、GEPIA和Bloodspot数据库评估SPAG6表达与患者生存之间的关系。CCK-8法检测细胞活力。流式细胞术检测细胞凋亡和细胞周期。结果：数据库分析显示AML中SPAG6表达升高。随后的RT-qPCR证实了AML、MDS、MPN和ALL样本中SPAG6的高表达。临床数据分析表明，AML患者中SPAG6表达与风险分层呈正相关。值得注意的是，研究发现高SPAG6表达的AML患者的总生存时间比低SPAG6表达的患者短。此外，在AML细胞系HL60中，SPAG6敲低可促进细胞凋亡，并将细胞周期阻滞在G1期。结论：因此，我们认为SPAG6可能是AML的促肿瘤因子。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

International Journal of Laboratory Hematology 医学-血液学

CiteScore

4.50

自引率

6.70%

发文量

211

审稿时长

6-12 weeks

期刊介绍： The International Journal of Laboratory Hematology provides a forum for the communication of new developments, research topics and the practice of laboratory haematology. The journal publishes invited reviews, full length original articles, and correspondence. The International Journal of Laboratory Hematology is the official journal of the International Society for Laboratory Hematology, which addresses the following sub-disciplines: cellular analysis, flow cytometry, haemostasis and thrombosis, molecular diagnostics, haematology informatics, haemoglobinopathies, point of care testing, standards and guidelines. The journal was launched in 2006 as the successor to Clinical and Laboratory Hematology, which was first published in 1979. An active and positive editorial policy ensures that work of a high scientific standard is reported, in order to bridge the gap between practical and academic aspects of laboratory haematology.